{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive+Bladder+Cancer",
    "query": {
      "condition": "HER2-positive Bladder Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive+Bladder+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T16:40:20.901Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04585750",
      "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Malignant Neoplasm",
        "Metastatic Cancer",
        "Metastatic Solid Tumor",
        "Lung Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Prostate Cancer",
        "Colorectal Cancer",
        "Breast Cancer",
        "Other Cancer",
        "Locally Advanced",
        "Head and Neck Cancer",
        "Gall Bladder Cancer",
        "Small Cell Lung Cancer",
        "Small Cell Lung Cancer ( SCLC )",
        "Small Cell Lung Carcinoma",
        "NSCLC",
        "NSCLC (Non-small Cell Lung Cancer)",
        "SCLC",
        "Non-Small Cell Lung Carcinoma",
        "Triple Negative Breast Cancer",
        "TNBC",
        "HER2+ Breast Cancer",
        "Non-Small Cell Lung Cancer",
        "ER/PR Positive Breast Cancer",
        "HER2- Breast Cancer",
        "HER2-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "ER/PR(+), Her2(-) Breast Cancer"
      ],
      "interventions": [
        {
          "name": "rezatapopt",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PMV Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2020-10-29",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 32,
      "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04585750"
    },
    {
      "nct_id": "NCT06253871",
      "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Mutation-Related Tumors",
        "HER2",
        "HER2-positive Breast Cancer",
        "HER2 + Breast Cancer",
        "Brain Metastases From Solid Tumors",
        "Brain Metastases From HER2 and Breast Cancer",
        "CNS Metastases",
        "HER2-Positive Solid Tumors",
        "NSCLC (Non-small Cell Lung Cancer)",
        "HER2-positive Bladder Cancer",
        "HER2-positive Colorectal Cancer",
        "HER2 + Gastric Cancer",
        "HER2-positive Gastroesophageal Cancer"
      ],
      "interventions": [
        {
          "name": "IAM1363",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Iambic Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 383,
      "start_date": "2024-03-25",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 29,
      "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06253871"
    },
    {
      "nct_id": "NCT06257264",
      "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Hormone-receptor-positive Breast Cancer",
        "Hormone Receptor Positive HER-2 Negative Breast Cancer",
        "Advanced Solid Tumor",
        "Endometrial Cancer",
        "Prostate Cancer",
        "TNBC - Triple-Negative Breast Cancer",
        "GastroEsophageal Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "BG-68501",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "BGB-43395",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeiGene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2024-03-11",
      "completion_date": "2026-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 6,
      "location_summary": "Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06257264"
    },
    {
      "nct_id": "NCT04561362",
      "title": "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urinary Bladder Neoplasm",
        "Triple Negative Breast Neoplasms",
        "Hormone Receptor Positive, HER2-negative Neoplasms",
        "Hormone Receptor Positive, HER2-low Neoplasms",
        "Breast Neoplasms",
        "Non-Small-Cell Lung Neoplasms",
        "Ovarian Neoplasm",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BT8009",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BicycleTx Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 329,
      "start_date": "2020-07-17",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 9,
      "location_summary": "Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04561362"
    },
    {
      "nct_id": "NCT07124000",
      "title": "DESTINY-PANTUMOUR04",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenocarcinoma (NOS)",
        "Anal Cancer",
        "Bladder Cancer",
        "Cervical Cancer",
        "Endometrial Cancer",
        "Esophageal Cancer",
        "Gall Bladder Cancer",
        "Gastrointestinal Stromal Tumour",
        "Head and Neck Cancer",
        "Liver Cancer",
        "Melanoma",
        "Mouth Cancer",
        "Nasopharangeal Cancer",
        "Neuroendocrine, Gastrointestinal Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Renal Cell Carcinoma",
        "Salivary Gland Cancer",
        "Sarcoma",
        "Small Cell Lung Cancer",
        "Testicular Cancer",
        "Throat Cancer",
        "Thyroid Cancer",
        "Urethral Cancer",
        "Vaginal Cancer",
        "Vulvar Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-09-18",
      "completion_date": "2028-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bullhead City",
          "state": "Arizona"
        },
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07124000"
    },
    {
      "nct_id": "NCT04602117",
      "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2 Low",
        "SYD-985",
        "SYD985",
        "Vic-trastuzumab Duocarmazine",
        "Metastatic Cancer",
        "Metastatic Breast Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic",
        "HER2 Low Breast Cancer",
        "GastroEsophageal Cancer",
        "Gastroesophageal Adenocarcinoma",
        "Endometrium Tumor",
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "HER2-positive Gastric Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER-2 Protein Overexpression",
        "HER2 Low HR Positive",
        "HR Positive",
        "Hormone Receptor-positive Breast Cancer",
        "Estrogen Receptor Positive Tumor",
        "Progesterone Receptor-positive Breast Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Negative Breast Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-07-28",
      "completion_date": "2021-11-17",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04602117"
    },
    {
      "nct_id": "NCT03650348",
      "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER2-positive Bladder Cancer",
        "HER2-positive Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PRS-343 in Combination with Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pieris Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-08-21",
      "completion_date": "2022-08-11",
      "has_results": false,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03650348"
    },
    {
      "nct_id": "NCT04660929",
      "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive",
        "Adenocarcinoma",
        "Bile Duct Cancer",
        "Biliary Tract Cancer",
        "Bladder Cancer",
        "Breast Cancer",
        "Breast Neoplasm",
        "Carcinoma, Ductal",
        "Carcinoma, Hepatocellular",
        "Cancer",
        "Lung Cancer, Non-Small-Cell",
        "Carcinoma, Ovarian Epithelial",
        "Carcinoma, Small Cell",
        "Carcinoma, Squamous",
        "Carcinoma, Transitional Cell",
        "Colorectal Cancer",
        "Esophagogastric Junction Neoplasms",
        "Inflammatory Breast Cancer",
        "Stomach Neoplasms",
        "Malignant Neoplasms",
        "Ovarian Neoplasms",
        "Pancreatic Cancer",
        "HER2-positive Solid Tumors",
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER-2 Protein Overexpression",
        "HER-2 Gene Amplification",
        "Prostate Cancer",
        "Head and Neck Cancer",
        "Endometrial Cancer",
        "Lung Cancer, Small Cell"
      ],
      "interventions": [
        {
          "name": "CT-0508",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Carisma Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2021-02-02",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04660929"
    },
    {
      "nct_id": "NCT03330561",
      "title": "PRS-343 in HER2-Positive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER2-positive Bladder Cancer",
        "HER2-positive Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PRS-343",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pieris Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2017-09-13",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03330561"
    },
    {
      "nct_id": "NCT00447226",
      "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Oral lapatinib tablets or placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-05",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2012-06-12",
      "last_synced_at": "2026-06-25T16:40:20.901Z",
      "location_count": 20,
      "location_summary": "Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00447226"
    }
  ]
}